Company intelligence / Profile preview
Kura Oncology
San Diego, California, United Statesorpha.net ↗
- Ownership
- Public · KURA
- Development stage
- Phase 2
01
Overview
Ziftomenib achieved its primary endpoint in the KOMET-001 registrational trial for relapsed/refractory NPM1-mutant AML, with NDA submission planned for Q2 2025. Phase 3 trials in frontline AML settings are being initiated with topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028[9].
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule drug candidates
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Kyowa Kirin (global strategic collaboration for ziftomenib)
04
Financials
- Market cap
- $1B
- Total revenue
- $20.9M
- Enterprise value
- $532.5M
Beyond the preview
Go deeper on Kura Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kura Oncology.